53 phd-studenship-in-computer-vision-and-machine-learning Fellowship positions at University of Birmingham
Sort by
Refine Your Search
-
research findings by helping to write publications, present at conferences and regular team meetings Supervise students on research related work and provide guidance to PhD students where appropriate
-
contribute to the creation of knowledge by undertaking a specified range of activities within an established research programme and/or specific research project. Our international group of highly motivated and
-
regular team meetings Supervise students on research related work and provide guidance to PhD students where appropriate to the discipline Contribute to developing new models, techniques and methods as
-
the potential to impact on protected groups and take appropriate action. Desirable Skills: Experience with machine learning or natural language processing. Knowledge of econometric methods for policy evaluation
-
clearly. Ability to assess resource requirements and use effectively. Ability to identify and learn new techniques and software skills, through self-study, training and/or CPD. Work within specified
-
development of future proposals for funding, into AI for renewable energy. You will consider ways in which the integration of machine learning algorithms might support the wider integration of, and uptake
-
guidance to PhD students where appropriate to the discipline Contribute to developing new models, techniques and methods Undertake management/administration arising from research Contribute to Departmental
-
and provide guidance to PhD students where appropriate to the discipline Contribute to developing new models, techniques and methods Undertake management/administration arising from research Contribute
-
research programme and/or specific research project. The Intellectual Disabilities Research Institute (IDRIS) is an applied cross-University research institute established in October 2024 with
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor